Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ann (Annie) W Silk
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
- University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- University of Kansas Cancer Center - North
Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
- University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Baylor College of Medicine/dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Sept 2017
- Primary completion
- 1 Sept 2027
- Completion
- 1 Sept 2027
- Last update posted
- 13 May 2026
- Registered enrollment
- 68
- Registry id
- NCT02978625
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.